Zev Wainberg, MD
Hematology & Oncology · Santa Monica, CANPI 1104850932
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $472,882 of the $761,190 with a category attached, or 62.1%. 42 manufacturers reported payments, led by Merck at 27.4% of the total. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $1749.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$209K
- Amgen$48K
- Pfizer$38K
- Astrazeneca UK Limited$36K
- Bayer$35K
- Daiichi Sankyo Inc.$34K
- plus $361K from 36 others
Across 826 payments — averaging $22,427 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3.7M
- Novartis$3.1M
- AstraZeneca$1.4M
- Amgen$1.3M
- Merck$1.3M
- Pfizer$1.3M
- plus $6.4M from 19 others
What the payments were for
- Consulting fees$472,88262%
- Speaking & faculty fees$152,31420%
- Travel & lodging$129,64417%
- Food & beverage$6,2961%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$761,190 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Santa Monica
- Omid HamidSanta Monica$809K
- Richard FinnSanta Monica$784K
- Saeed SadeghiSanta Monica$696K
- Aditya BardiaSanta Monica$593K
- Steven OdaySanta Monica$270K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.